See more : Aclaris Therapeutics, Inc. (ACRS) Income Statement Analysis – Financial Results
Complete financial analysis of Alexander’s, Inc. (ALX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alexander’s, Inc., a leading company in the REIT – Retail industry within the Real Estate sector.
You may be interested
- Confidence Finance and Trading Limited (CONFINT.BO) Income Statement Analysis – Financial Results
- Hunan Sundy Science and Technology Co., Ltd. (300515.SZ) Income Statement Analysis – Financial Results
- ZongTai Real Estate Development Co., Ltd. (3056.TW) Income Statement Analysis – Financial Results
- PM&E, Inc. (PMEA) Income Statement Analysis – Financial Results
- Power Financial Group Limited (0397.HK) Income Statement Analysis – Financial Results
Alexander's, Inc. (ALX)
About Alexander's, Inc.
Alexander's, Inc. is a real estate investment trust which has seven properties in the greater New York City metropolitan area.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 224.96M | 205.81M | 206.15M | 199.14M | 226.35M | 232.83M | 230.57M | 226.94M | 207.92M | 200.81M | 196.46M | 191.31M | 204.27M | 183.83M | 168.38M | 163.85M | 170.01M | 179.58M | 139.18M | 110.15M | 75.45M | 55.48M | 69.14M | 43.67M | 47.80M | 22.50M | 21.60M | 25.20M | 2.50M | 13.20M | 4.90M | 2.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 101.21M | 90.45M | 21.14M | 88.40M | 89.74M | 93.78M | 85.13M | 82.23M | 76.22M | 69.90M | 64.68M | 61.76M | 84.94M | 78.65M | 73.34M | 77.11M | 70.50M | 71.98M | 64.87M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 123.75M | 115.37M | 185.01M | 110.74M | 136.61M | 139.05M | 145.45M | 144.70M | 131.70M | 130.92M | 131.78M | 129.56M | 119.33M | 105.18M | 95.04M | 86.74M | 99.51M | 107.60M | 74.30M | 110.15M | 75.45M | 55.48M | 69.14M | 43.67M | 47.80M | 22.50M | 21.60M | 25.20M | 2.50M | 13.20M | 4.90M | 2.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 55.01% | 56.05% | 89.75% | 55.61% | 60.35% | 59.72% | 63.08% | 63.76% | 63.34% | 65.19% | 67.08% | 67.72% | 58.42% | 57.21% | 56.44% | 52.94% | 58.53% | 59.92% | 53.39% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.28 | 0.63 | 0.21 | 0.39 | 0.36 | 0.35 | 0.38 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.34M | 6.11M | 5.92M | 6.31M | 5.77M | 5.34M | 5.25M | 5.44M | 5.41M | 5.03M | 5.28M | 5.16M | 84.94M | 86.44M | 101.59M | 91.68M | -38.34M | 154.84M | 32.39M | 81.29M | 48.92M | 3.96M | 3.86M | 3.89M | 3.70M | 4.10M | 3.90M | 4.40M | 5.10M | 3.60M | 1.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.34M | 6.11M | 5.92M | 6.31M | 5.77M | 5.34M | 5.25M | 5.44M | 5.41M | 5.03M | 5.28M | 5.16M | 84.94M | 86.44M | 101.59M | 91.68M | -38.34M | 154.84M | 32.39M | 81.29M | 48.92M | 3.96M | 3.86M | 3.89M | 3.70M | 4.10M | 3.90M | 4.40M | 5.10M | 3.60M | 1.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | 120.24M | 124.03M | 120.76M | 121.09M | 126.86M | 120.05M | 116.04M | 107.30M | 99.09M | 93.66M | 90.57M | 3.06M | -3.44M | -29.59M | -4.68M | 93.34M | 94.16M | 84.61M | -184.58M | -128.43M | -12.97M | -23.14M | -20.93M | -28.40M | -17.60M | -4.60M | 9.00M | -3.50M | -9.50M | -4.10M | -134.90M | -4.20M | -3.90M | 20.90M | -4.30M | 1.30M | 2.70M |
| Operating Expenses | 6.34M | 126.35M | 129.95M | 127.07M | 126.86M | 132.20M | 125.30M | 121.48M | 112.71M | 104.13M | 98.94M | 95.73M | 88.00M | 83.00M | 72.00M | 87.00M | 55.00M | 249.00M | 117.00M | -103.30M | -79.51M | -9.01M | -19.28M | -17.04M | -24.70M | -13.50M | -700.00K | 13.40M | 1.60M | -5.90M | -2.90M | -134.90M | -4.20M | -3.90M | 20.90M | -4.30M | 1.30M | 2.70M |
| Cost & Expenses | 107.55M | 126.35M | 129.95M | 127.07M | 126.86M | 132.20M | 125.30M | 121.48M | 112.71M | 104.13M | 98.94M | 95.73M | 88.00M | 83.00M | 72.00M | 87.00M | 55.00M | 249.00M | 117.00M | -103.30M | -79.51M | -9.01M | -19.28M | -17.04M | -24.70M | -13.50M | -700.00K | 13.40M | 1.60M | -5.90M | -2.90M | -134.90M | -4.20M | -3.90M | 20.90M | -4.30M | 1.30M | 2.70M |
| Interest Income | 22.25M | 6.77M | 639.00K | 2.67M | 8.24M | 12.55M | 6.72M | 3.31M | 5.95M | 2.43M | 1.53M | 177.00K | 2.67M | 851.00K | 2.85M | 15.22M | 27.35M | 28.26M | 14.77M | 1.57M | 1.98M | 2.18M | 3.24M | 1.12M | 1.00M | 1.00M | 700.00K | 2.90M | 1.70M | 4.80M | 700.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 58.30M | 28.60M | 19.69M | 24.20M | 38.90M | 44.53M | 31.47M | 22.24M | 24.24M | 32.07M | 44.54M | 45.65M | 52.66M | 58.37M | 57.99M | 62.47M | 65.32M | 71.98M | 62.68M | 40.32M | 13.69M | 22.89M | 22.47M | 21.42M | 17.60M | 15.10M | 13.40M | 13.90M | 13.20M | 3.30M | 900.00K | 0.00 | -4.20M | -3.90M | 20.90M | -4.30M | 1.30M | 2.70M |
| Depreciation & Amortization | 32.90M | 126.35M | 126.47M | 135.67M | 108.54M | 116.23M | 95.00M | 92.59M | 33.67M | 31.92M | 31.40M | 36.36M | 37.09M | 34.85M | 30.45M | 26.72M | 24.99M | 24.46M | 22.84M | 18.82M | 11.31M | 8.97M | 7.97M | 8.05M | 7.50M | 5.70M | 4.50M | 4.10M | 4.70M | 2.30M | 800.00K | 5.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | 117.41M | 117.69M | 111.43M | 109.86M | 144.25M | 139.67M | 150.66M | 139.27M | 126.29M | 125.89M | 126.50M | 87.10M | 170.69M | 158.03M | 184.44M | 166.42M | 0.00 | 3.95M | 167.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.80M | 0.00 | 2.80M | 0.00 | -4.20M | -3.90M | 20.90M | -4.30M | 1.30M | 2.70M |
| EBITDA Ratio | 52.19% | 57.18% | 54.05% | 55.17% | 63.73% | 65.14% | 65.34% | 63.96% | 64.85% | 65.26% | 66.39% | 69.06% | 83.56% | 85.96% | 109.54% | 101.57% | 120.38% | 18.23% | 120.53% | 23.30% | 9.62% | 99.92% | 83.64% | 79.40% | 64.02% | 65.33% | 117.59% | 169.44% | 352.00% | 72.73% | 57.14% | -5,763.64% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 117.41M | 86.23M | 76.84M | 74.74M | 107.73M | 100.62M | 105.27M | 105.46M | 95.21M | 96.69M | 97.52M | 95.58M | 133.60M | 123.18M | 154.00M | 139.70M | 179.66M | 8.27M | 144.92M | 6.85M | -4.05M | 46.47M | 49.86M | 26.62M | 23.10M | 9.00M | 20.90M | 38.60M | 4.10M | 7.30M | 2.00M | -132.70M | -4.20M | -3.90M | 20.90M | -4.30M | 1.30M | 2.70M |
| Operating Income Ratio | 52.19% | 41.90% | 37.27% | 37.53% | 47.60% | 43.22% | 45.66% | 46.47% | 45.79% | 48.15% | 49.64% | 49.96% | 65.41% | 67.01% | 91.46% | 85.27% | 105.68% | 4.61% | 104.13% | 6.22% | -5.37% | 83.76% | 72.11% | 60.97% | 48.33% | 40.00% | 96.76% | 153.17% | 164.00% | 55.30% | 40.82% | -6,031.82% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -15.00M | -21.83M | 21.45M | -21.54M | -70.77M | -77.06M | 0.00 | -18.94M | -18.29M | -29.63M | -43.01M | -45.48M | -49.99M | -58.76M | -55.15M | -47.26M | -39.14M | -36.39M | -163.61M | -66.43M | -25.00M | -31.86M | -30.44M | -29.47M | -25.10M | -20.80M | -17.90M | -18.00M | -13.20M | -5.60M | -900.00K | 118.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 102.41M | 57.63M | 130.58M | 41.94M | 60.08M | 56.65M | 80.51M | 86.53M | 76.92M | 67.06M | 54.50M | 50.11M | 80.94M | 64.80M | 96.01M | 77.23M | 114.34M | -63.71M | 21.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -9.10M | 0.00 | 1.10M | -14.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 45.52% | 28.00% | 63.34% | 21.06% | 26.54% | 24.33% | 34.92% | 38.13% | 36.99% | 33.39% | 27.74% | 26.19% | 39.63% | 35.25% | 57.02% | 47.14% | 67.26% | -35.48% | 15.30% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -364.00% | 0.00% | 22.45% | -659.09% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 28.60M | 17.34M | 24.20M | 38.90M | 4.00K | 3.00K | 48.00K | 8.00K | -341.00K | -160.00K | 64.00K | -105.00K | -2.64M | -36.94M | 941.00K | 65.32M | 11.27M | 62.68M | 40.32M | 13.69M | 22.89M | 22.47M | 21.42M | 17.60M | 15.10M | 13.40M | 13.90M | -1.40M | 3.30M | 200.00K | 100.00K | 4.20M | 3.90M | -20.90M | 4.30M | -1.30M | -2.70M |
| Net Income | 102.41M | 29.03M | 132.93M | 17.74M | 21.17M | 32.84M | 80.51M | 86.48M | 76.91M | 67.93M | 56.92M | 674.39M | 79.42M | 66.43M | 132.19M | 76.29M | 114.34M | -74.98M | 82.24M | -33.47M | -17.74M | 23.58M | 27.39M | 5.20M | 5.50M | -6.10M | 7.50M | 24.70M | 2.40M | 4.00M | 900.00K | -132.80M | -4.20M | -3.90M | 20.90M | -4.30M | 1.30M | 2.70M |
| Net Income Ratio | 45.52% | 14.10% | 64.48% | 8.91% | 9.35% | 14.11% | 34.92% | 38.11% | 36.99% | 33.82% | 28.97% | 352.51% | 38.88% | 36.14% | 78.51% | 46.56% | 67.26% | -41.76% | 59.09% | -30.39% | -23.51% | 42.51% | 39.61% | 11.90% | 11.51% | -27.11% | 34.72% | 98.02% | 96.00% | 30.30% | 18.37% | -6,036.36% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 19.97 | 5.66 | 25.49 | 3.46 | 4.14 | 6.42 | 15.74 | 16.91 | 15.04 | 13.29 | 11.14 | 132.04 | 15.55 | 13.01 | 25.90 | 15.05 | 22.68 | -14.92 | 16.38 | -7.55 | -3.55 | 4.72 | 5.48 | 1.04 | 1.10 | -1.21 | 1.49 | 4.94 | 0.49 | 0.81 | 1.88 | -26.69 | -0.84 | -0.79 | 4.20 | -0.86 | 0.27 | 0.59 |
| EPS Diluted | 19.97 | 5.66 | 25.49 | 3.46 | 4.14 | 6.42 | 15.74 | 16.91 | 15.04 | 13.29 | 11.14 | 132.04 | 15.55 | 13.01 | 25.89 | 14.96 | 22.44 | -14.92 | 16.19 | -7.55 | -3.55 | 4.72 | 5.48 | 1.04 | 1.10 | -1.21 | 1.49 | 4.94 | 0.49 | 0.81 | 1.88 | -26.69 | -0.84 | -0.79 | 4.20 | -0.86 | 0.27 | 0.59 |
| Weighted Avg Shares Out | 5.13M | 5.13M | 5.12M | 5.12M | 5.12M | 5.12M | 5.12M | 5.11M | 5.11M | 5.11M | 5.11M | 5.11M | 5.11M | 5.11M | 5.10M | 5.07M | 5.04M | 5.03M | 5.02M | 4.43M | 5.00M | 5.00M | 5.00M | 5.00M | 5.00M | 5.04M | 5.03M | 5.00M | 4.90M | 4.94M | 5.00M | 4.98M | 5.00M | 4.94M | 4.98M | 5.00M | 4.81M | 4.58M |
| Weighted Avg Shares Out (Dil) | 5.13M | 5.13M | 5.12M | 5.12M | 5.12M | 5.12M | 5.12M | 5.11M | 5.11M | 5.11M | 5.11M | 5.11M | 5.11M | 5.11M | 5.11M | 5.10M | 5.10M | 5.03M | 5.08M | 4.43M | 5.00M | 5.00M | 5.00M | 5.02M | 5.02M | 5.04M | 5.03M | 5.00M | 5.00M | 5.00M | 5.00M | 4.98M | 5.00M | 4.94M | 4.98M | 5.00M | 4.81M | 4.58M |
ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced that the Company will host an...
Alexander's Announces Second Quarter Earnings Release Date and Vornado Realty Trust Quarterly Conference Call
PARAMUS, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it will file its quarterly report on Form 10-Q for the quarter ended June 30, 2024 with the U.S. Securities and Exchange Commission and issue its...
Alexander's Inc.: Numerous Signs Of Distress
Office REITs have gained modestly this year, but face challenges due to the WFH trend and mounting defaults in commercial real estate loans. Alexanders, Inc. is a small-cap REIT with a portfolio of office and retail properties in New York...
Three Office REITs To Sell With Weak Balance Sheets
There will likely be a major sell-off in REITs in the next 2-5 years. Weak REITs with messy balance sheets, weak forecasts for FFO growth, unsafe dividends, and/or overvaluation are likely to suffer the most damage in any downturn. This...
ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation
ALX Oncology valuation has dropped below $500 million, presenting new studies at venues like ASCO, reaching a point of inflection. Evorpacept is the main focus, showing promising activity signals in gastric cancer and urothelial carcinoma, with upcoming data updates and...
ALX Resources Corp. Acquires Blackbird Project in Northern Saskatchewan
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - ALX Resources Corp. (TSXV: AL) (FSE: 6LLN) (OTC: ALXEF) ("ALX" or the "Company") is pleased to announce that it has acquired the Blackbird Project ("Blackbird", or the "Project") in northern Saskatchewan,...
ALX Resources Corp. Receives Analytical Results from the Gibbons Creek Uranium Project, Athabasca Basin, Saskatchewan
Vancouver, British Columbia--(Newsfile Corp. - June 13, 2024) - ALX Resources Corp. (TSXV: AL) (FSE: 6LLN) (OTC: ALXEF) ("ALX" or the "Company") is pleased to announce the results of the 2024 winter drilling program and upcoming summer 2024 exploration plans at...
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
SOUTH SAN FRANCISCO, Calif., June 02, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today presented data from its Phase 1...
ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that management will participate in...
ALX Resources Corp. Amends Hook-Carter Uranium Project Joint Venture Agreement with Denison Mines - Exploration Planned for 2024
Vancouver, British Columbia--(Newsfile Corp. - May 23, 2024) - ALX Resources Corp. (TSXV: AL) (FSE: 6LLN) (OTC: ALXEF) ("ALX" or the "Company") is pleased to announce it has entered into an amending agreement (the "Amendment") with Denison Mines Corp. ("Denison") whereby ALX may...
Source: https://incomestatements.info
Category: Stock Reports